Hyperfine Inc. (HYPR)
NASDAQ:HYPR
Want to see HYPR full AI Analyst Report?
Top Page
Hyperfine
(NASDAQ:HYPR)
Select Model
Select Model
Rating:52Neutral
Price Target:
$1.50
▲(14.50% Upside)
Action:Reiterated
Date:05/22/26
The score is primarily held back by weak financial performance—large ongoing losses, continued cash burn, and equity erosion—despite improving revenue and gross margin. The latest earnings call adds support via reiterated growth and margin guidance and signs of better operating discipline, while technicals are mixed (longer-term trend supportive but near-term soft). Valuation provides limited support given negative earnings and no dividend yield.
Positive Factors
Revenue & unit growth
Sustained double‑digit unit and revenue growth indicates genuine commercial traction across hospitals, neurology offices and international pilots. Durable unit adoption supports recurring service and software revenue, strengthens sales referenceability, and underpins scalable top‑line expansion over 2–6 months.
Negative Factors
High cash burn & negative FCF
Material and persistent cash outflows require external funding to sustain operations. Continued negative free cash flow constrains capital allocation, increases financing needs, and risks slower scaling if revenue growth stalls, making long‑term self‑funding unattainable absent margin or volume inflection.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & unit growth
Sustained double‑digit unit and revenue growth indicates genuine commercial traction across hospitals, neurology offices and international pilots. Durable unit adoption supports recurring service and software revenue, strengthens sales referenceability, and underpins scalable top‑line expansion over 2–6 months.
Read all positive factors
Hyperfine (HYPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$147.91M
Dividend YieldN/A
Average Volume (3M)677.65K
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue Growth30.66%
EPS Growth25.64%
CountryUS
Employees111
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.41
Shares Outstanding84,215,050
10 Day Avg. Volume540,288
30 Day Avg. Volume677,654
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)2.25
Price to Sales (P/S)6.80
P/FCF Ratio-3.17
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue5.53
Enterprise Value/Gross Profit10.79
Enterprise Value/Ebitda-2.43
Forecast
1Y Price Target
$2.17Price Target Upside65.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$20.03M
Hyperfine Business Overview & Revenue Model
Company Description
Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. Th...
How the Company Makes Money
Hyperfine generates revenue primarily by selling or leasing its Swoop Portable MR Imaging systems to healthcare providers, which may include associated accessories and installation. The company also earns recurring revenue from post-sale offerings...
Hyperfine Earnings Call Summary
Earnings Call Date:May 12, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call highlights strong commercial traction for the next-generation subsystem with 83% YoY revenue growth, significant gross margin expansion (~940 bps), improving cash burn, important regulatory and clinical milestones (CE/UKCA, Optive AI launch, >50% enrollment in contrast PMR), and reiterated conservative yet growth-oriented FY2026 guidance. Offsetting these positives are continued net losses, meaningful full‑year cash burn requirements, reliance on a debt facility for liquidity, longer sales cycles for IDNs that can delay larger deals, and the fact that contrast indication and broader international scale are still pending. Overall, the progress, momentum, and margin improvement dominate the risks in the near term.Positive Updates
Strong Revenue Growth
Q1 revenue of $3.9M, up 83% year-over-year from $2.1M; sold 10 units versus 6 in the prior-year period, driven largely by next-generation subsystem sales across hospitals, neurology offices and international.
Negative Updates
Net Loss and Ongoing Quarterly Losses
Net loss of $8.6M in Q1 2026 (loss per share $0.09) versus $9.4M prior-year — company remains unprofitable with continued negative net income despite improvements.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Revenue Growth
Q1 revenue of $3.9M, up 83% year-over-year from $2.1M; sold 10 units versus 6 in the prior-year period, driven largely by next-generation subsystem sales across hospitals, neurology offices and international.
Read all positive updates
Company Guidance
Hyperfine reiterated 2026 guidance calling for revenue of $20.0–$22.0 million (midpoint ≈ 55% YoY growth), annual gross margin of 50–55% with H2 margins expected to exceed H1 and management aiming to sustain >50%, and total cash burn of $26–28 million for the year (midpoint ≈ a 10% YoY decline); the guidance includes quarterly debt payments of roughly $400k and the company says its cash runway extends into 2028 (inclusive of the $15M initial debt tranche). Management noted a $40.8M cash balance as of 3/31/2026 (inclusive of the $15M tranche) and cited Q1 results that support the outlook: Q1 revenue $3.9M (up 83% YoY), 10 units sold vs 6 a year ago, Q1 gross margin 50.7% (vs 41.3%, +940 bps), Q1 net cash burn excluding financing $8.8M (vs $10.1M, ~13% improvement), Q1 net loss $8.6M ($0.09/share), R&D $3.8M (down ~24%), and SG&A $6.7M (flat).Hyperfine Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.33M | 13.56M | 12.89M | 11.03M | 6.81M | 1.50M |
| Gross Profit | 7.85M | 6.75M | 5.89M | 4.76M | 907.00K | -1.17M |
| EBITDA | -34.92M | -34.88M | -42.22M | -47.06M | -72.86M | -64.14M |
| Net Income | -34.78M | -35.57M | -40.72M | -44.24M | -73.16M | -64.83M |
Balance Sheet | ||||||
| Total Assets | 60.34M | 55.26M | 58.90M | 94.20M | 134.05M | 202.47M |
| Cash, Cash Equivalents and Short-Term Investments | 40.78M | 35.09M | 37.65M | 75.18M | 118.24M | 188.50M |
| Total Debt | 0.00 | 314.00K | 269.00K | 185.00K | 0.00 | 0.00 |
| Total Liabilities | 25.98M | 14.26M | 9.86M | 9.80M | 10.33M | 16.25M |
| Stockholders Equity | 34.36M | 41.01M | 49.04M | 84.40M | 123.72M | 186.23M |
Cash Flow | ||||||
| Free Cash Flow | -28.66M | -29.13M | -39.15M | -42.61M | -72.92M | -49.89M |
| Operating Cash Flow | -27.71M | -27.95M | -38.77M | -41.81M | -72.34M | -47.18M |
| Investing Cash Flow | -955.00K | -1.19M | -383.00K | -804.00K | -585.00K | -2.71M |
| Financing Cash Flow | 36.41M | 27.50M | 1.02M | 174.00K | 7.00K | 176.77M |
Hyperfine Technical Analysis
Neutral
1.31
Price Trends
1.36
Positive
1.24
Positive
1.25
Positive
Market Momentum
0.04
Positive
49.85
Neutral
27.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPR, the sentiment is Neutral. The current price of 1.31 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.36, and above the 200-day MA of 1.25, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 49.85 is Neutral, neither overbought nor oversold. The STOCH value of 27.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HYPR.
Hyperfine Risk Analysis
Hyperfine disclosed 79 risk factors in its most recent earnings report. Hyperfine reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Hyperfine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $118.65M | 17.44 | 3.81% | ― | 2.25% | -19.05% | |
52 Neutral | $147.91M | -3.06 | -101.28% | ― | 30.66% | 25.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $16.14M | -1.30 | -211.73% | ― | 8.92% | 17.49% | |
44 Neutral | $8.48M | -0.56 | -335.47% | ― | 33.77% | -20.22% | |
43 Neutral | $7.07M | -0.16 | -247.60% | ― | ― | 36.00% |
* Healthcare Sector Average
HYPR
Hyperfine
1.49
0.95
173.90%
FONR
Fonar
18.90
4.76
33.72%
MODD
Modular Medical
4.34
-21.24
-83.04%
RBOT
Vicarious Surgical
0.99
-6.43
-86.63%
VVOS
Vivos Therapeutics
0.61
-1.66
-73.13%
ICCM
Icecure Medical
0.24
-0.88
-78.83%
Hyperfine Corporate Events
Executive/Board ChangesShareholder Meetings
Hyperfine Shareholders Reelect Board and Ratify Auditor
Positive
May 21, 2026
On May 21, 2026, Hyperfine, Inc. held its 2026 annual meeting of stockholders, with holders of Class A and Class B common stock representing about 89.89% of the company’s total voting power present, establishing a quorum. Stockholders were e...
Business Operations and StrategyPrivate Placements and Financing
Hyperfine Secures $40 Million Term Loan Financing Agreement
Positive
Mar 18, 2026
On March 18, 2026, Hyperfine, Inc. entered into a Loan and Security Agreement with Horizon Technology Finance Corporation for a senior secured term loan facility of up to $40 million, of which $15 million was drawn at closing for working capital a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.